Last reviewed · How we verify
ARV regimen chosen by treating physician
ARV regimen chosen by treating physician is a Antiretroviral combination therapy Small molecule drug developed by Kristine Patterson, MD. It is currently in Phase 2 development for HIV-1 infection. Also known as: Zidovudine: ZDV, Retrovir, Retrovis, AZT (Azidothymidine), Lamivudine: 3TC, Zeffix, Epivir, Epivir-HBV, Emtricitabine: FTC, Emtriva, Abacivir: Ziagen.
This is a physician-selected antiretroviral regimen tailored to individual patient characteristics and viral resistance profile.
This is a physician-selected antiretroviral regimen tailored to individual patient characteristics and viral resistance profile. Used for HIV-1 infection.
At a glance
| Generic name | ARV regimen chosen by treating physician |
|---|---|
| Also known as | Zidovudine: ZDV, Retrovir, Retrovis, AZT (Azidothymidine), Lamivudine: 3TC, Zeffix, Epivir, Epivir-HBV, Emtricitabine: FTC, Emtriva, Abacivir: Ziagen, Tenofovir: TDF, Viread |
| Sponsor | Kristine Patterson, MD |
| Drug class | Antiretroviral combination therapy |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 2 |
Mechanism of action
ARV regimens chosen by treating physicians typically combine multiple antiretroviral drug classes (such as nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, or entry inhibitors) to suppress HIV replication through complementary mechanisms. The specific combination is individualized based on patient factors including viral load, CD4 count, comorbidities, drug interactions, and resistance testing results.
Approved indications
- HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Lipid abnormalities
- Hepatotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARV regimen chosen by treating physician CI brief — competitive landscape report
- ARV regimen chosen by treating physician updates RSS · CI watch RSS
- Kristine Patterson, MD portfolio CI
Frequently asked questions about ARV regimen chosen by treating physician
What is ARV regimen chosen by treating physician?
How does ARV regimen chosen by treating physician work?
What is ARV regimen chosen by treating physician used for?
Who makes ARV regimen chosen by treating physician?
Is ARV regimen chosen by treating physician also known as anything else?
What drug class is ARV regimen chosen by treating physician in?
What development phase is ARV regimen chosen by treating physician in?
What are the side effects of ARV regimen chosen by treating physician?
Related
- Drug class: All Antiretroviral combination therapy drugs
- Manufacturer: Kristine Patterson, MD — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection
- Also known as: Zidovudine: ZDV, Retrovir, Retrovis, AZT (Azidothymidine), Lamivudine: 3TC, Zeffix, Epivir, Epivir-HBV, Emtricitabine: FTC, Emtriva, Abacivir: Ziagen, Tenofovir: TDF, Viread
- Compare: ARV regimen chosen by treating physician vs similar drugs
- Pricing: ARV regimen chosen by treating physician cost, discount & access